Individualized prediction of survival benefit from postoperative radiotherapy for patients with malignant pleural mesothelioma

被引:1
作者
Wo, Yang [1 ,2 ,3 ]
Peng, Yizhou [1 ,2 ,3 ]
Wu, Zhigang [1 ,2 ,3 ]
Liu, Pengcheng [1 ,2 ,3 ]
Shang, Yan [1 ,2 ,3 ]
Shen, Xuxia [4 ,5 ,7 ]
Sun, Yihua [1 ,2 ,3 ,6 ]
机构
[1] Fudan Univ Shanghai Canc Ctr, State Key Lab Genet Engn, Shanghai, Peoples R China
[2] Fudan Univ, Dept Thorac Surg, Shanghai Canc Ctr, Shanghai, Peoples R China
[3] Fudan Univ, Inst Thorac Oncol, Shanghai, Peoples R China
[4] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China
[5] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai, Peoples R China
[6] Fudan Univ, Dept Thorac Surg, Shanghai Canc Ctr, 270 Dong An Rd, Shanghai 200032, Peoples R China
[7] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, 270 Dong An Rd, Shanghai 200032, Peoples R China
来源
CANCER MEDICINE | 2023年 / 12卷 / 11期
基金
中国国家自然科学基金;
关键词
nomogram; prognostic factor; radiotherapy; SEER; STAGING PROJECT PROPOSALS; FORTHCOMING 8TH EDITION; MODULATED RADIATION-THERAPY; EXTRAPLEURAL PNEUMONECTOMY; IASLC MESOTHELIOMA; TNM CLASSIFICATION; HEMITHORACIC RADIOTHERAPY; PROGNOSTIC-FACTORS; DESCRIPTORS; PATTERNS;
D O I
10.1002/cam4.5955
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: The role of postoperative radiotherapy (PORT) in malignant pleural mesothelioma (MPM) remains controversial and the eighth edition TNM staging scheme for MPM has not been fully verified. We aimed to develop an individualized prediction model for identifying optimal candidates for PORT among MPM patients who received surgery plus chemotherapy and externally validate the performance of the new TNM staging scheme.Materials and Methods: Detailed characteristics of MPM patients during 2004-2015 were retrieved from SEER registries. Propensity score matching (PSM) was conducted to reduce disparities of baseline characteristics (age, sex, histologic type, stage, and type of surgery) between the PORT group and no-PORT group. A novel nomogram was constructed based on independent prognosticators identified by multivariate Cox regression model. The discriminatory performance and degree of calibration were evaluated. We stratified patients into different risk groups according to nomogram total scores and estimated the survival benefit of PORT in different subgroups in order to identify the optimal candidates.Results: We identified 596 MPM patients, among which 190 patients (31.9%) received PORT. PORT conferred significant survival benefit in the unmatched population, while there was no significant survival difference favoring PORT in the matched population. The C-index of the new TNM staging scheme was closed to 0.5, which represented a poor discriminatory ability. A novel nomogram was constructed based on clinicopathological factors, including age, sex, histology, and N stage. We stratified patients into three risk groups. Subgroup analyses indicated that PORT was beneficial for high-risk group (p = 0.003) rather than low-risk group (p = 0.965) and intermediate-risk group (p = 0.661).Conclusion: We established a novel predictive model, which could make individualized prediction of survival benefit of PORT for MPM and could compensate for weakness in TNM staging system.
引用
收藏
页码:12452 / 12461
页数:10
相关论文
共 41 条
  • [1] Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles
    Andujar, Pascal
    Lacourt, Aude
    Brochard, Patrick
    Pairon, Jean-Claude
    Jaurand, Marie-Claude
    Jean, Didier
    [J]. JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART B-CRITICAL REVIEWS, 2016, 19 (5-6): : 151 - 172
  • [2] Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013-2017: A nationwide CAS registry analysis from the I-O Optimise initiative
    Baas, Paul
    Daumont, Melinda J.
    Lacoin, Laure
    Penrod, John R.
    Carroll, Robert
    Venkatesan, Sudhir
    Ubhi, Harveen
    Calleja, Alan
    Snee, Michael
    [J]. LUNG CANCER, 2021, 162 : 185 - 193
  • [3] Macroscopic complete resection is not associated with improved survival in patients with malignant pleural mesothelioma
    Batirel, Hasan Fevzi
    Metintas, Muzaffer
    Caglar, Hale Basak
    Ak, Guntulu
    Yumuk, Perran Fulden
    Ahiskali, Rengin
    Bozkurtlar, Emine
    Bekiroglu, Nural
    Lacin, Tunc
    Yildizeli, Bedrettin
    Yuksel, Mustafa
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2018, 155 (06) : 2724 - 2732
  • [4] Radical pleurectomy and chemoradiation for malignant pleural mesothelioma: The outcome of incomplete resections
    Boeluekbas, Servet
    Eberlein, Michael
    Fisseler-Eckhoff, Annette
    Schirren, Joachim
    [J]. LUNG CANCER, 2013, 81 (02) : 241 - 246
  • [5] Does Surgery Improve Survival of Patients with Malignant Pleural Mesothelioma?
    Bovolato, Pietro
    Casadio, Caterina
    Bille, Andrea
    Ardissone, Francesco
    Santambrogio, Luigi
    Ratto, Giovanni Battista
    Garofalo, Giuseppe
    Bedini, Amedeo Vittorio
    Garassino, Marina
    Porcu, Luca
    Torri, Valter
    Pastorino, Ugo
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (03) : 390 - 396
  • [6] Surgery in Malignant Pleural Mesothelioma
    Bueno, Raphael
    Opitz, Isabelle
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (11) : 1638 - 1654
  • [7] X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization
    Camp, RL
    Dolled-Filhart, M
    Rimm, DL
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (21) : 7252 - 7259
  • [8] Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
    Carbone, Michele
    Adusumilli, Prasad S.
    Alexander, H. Richard, Jr.
    Baas, Paul
    Bardelli, Fabrizio
    Bononi, Angela
    Bueno, Raphael
    Felley-Bosco, Emanuela
    Galateau-Salle, Francoise
    Jablons, David
    Mansfield, Aaron S.
    Minaai, Michael
    de Perrot, Marc
    Pesavento, Patricia
    Rusch, Valerie
    Severson, David T.
    Taioli, Emanuela
    Tsao, Anne
    Woodard, Gavitt
    Yang, Haining
    Zauderer, Marjorie G.
    Pass, Harvey, I
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2019, 69 (05) : 402 - 429
  • [9] Hemithoracic Intensity Modulated Radiation Therapy After Pleurectomy/Decortication for Malignant Pleural Mesothelioma: Toxicity, Patterns of Failure, and a Matched Survival Analysis
    Chance, William W.
    Rice, David C.
    Allen, Pamela K.
    Tsao, Anne S.
    Fontanilla, Hiral P.
    Liao, Zhongxing
    Chang, Joe Y.
    Tang, Chad
    Pan, Hubert Y.
    Welsh, James W.
    Mehran, Reza J.
    Gomez, Daniel R.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 91 (01): : 149 - 156
  • [10] Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience
    Curran, D
    Sahmoud, T
    Therasse, P
    van Meerbeeck, J
    Postmus, PE
    Giaccone, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) : 145 - 152